$VRTX
VRTX · Healthcare
- Market cap
- —
- Volume
- —
- P/E
- —
- Day range
- — – —
- 52w range
- — – —
- Analyst target
- —
AI Summary
Generating a unique summary for VRTX…
AI-generated for information only — not investment advice.
Share this ticker
$VRTX David Tepper and 2 other tracked billionaires hold it. $JNJ $NTRA $LLY https://billionairestrading.com/stocks/VRTX
Company summary
Cystic fibrosis and gene therapy.
Institutional ownership
Institutions hold —% · insiders —%
No institutional filings available for this ticker.
Hedge fund & billionaire activity
Insider transactions
No insider transactions reported.
Analyst ratings
Consensus score — (1 = strong buy, 5 = sell) · mean target —
No recent analyst actions.
Earnings
Next report: not scheduled
No earnings history available.
SEC filings
No filings indexed for this ticker.
Latest VRTX news
- Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?
They could both outperform the market over the medium term, but one appears to have a clear edge.
Fri, 04 Sep 2026 18:50:00 +0000
- How Is Vertex Pharmaceuticals' Stock Performance Compared to Other Biotech Stocks?
Vertex Pharmaceuticals has underperformed the Biotech industry over the past year, but analysts are moderately optimistic about the stock’s prospects.
Wed, 02 Sep 2026 15:44:06 +0000
- Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Wed, 02 Sep 2026 15:30:12 +0000
- Vertex (VRTX) Stock Trades At A Premium On Earnings Yet Looks Fair On Broader Checks
Vertex Pharmaceuticals stock has delivered strong multi year gains, and current valuation checks suggest the shares now look closer to fairly priced than clearly cheap or clearly expensive. Vertex Pharmaceuticals has returned 184.9% over the past 5 years, which puts extra focus on whether the current price still offers an appealing entry point for new money. Expectations for continued revenue and cash flow growth from its existing treatment portfolio can support today’s valuation, while any...
Wed, 02 Sep 2026 01:07:20 +0000
- Goldman Sachs refreshes conviction lists on both sides of the Atlantic
Investing.com -- Goldman Sachs updated its U.S. and European conviction lists for September, adding several new names as it refreshed its highest-conviction ideas heading into the autumn.
Tue, 01 Sep 2026 17:26:32 +0000
- Vertex Completes $10 Billion Crinetics Acquisition, Adding Rare Endocrine Growth Platform
The completed acquisition adds PALSONIFY and atumelnant to Vertex’s portfolio, with the two therapies carrying combined peak annual revenue potential of more than $5 billion according to the company. Key Investor TakeawaysVertex Pharmaceuticals (NASDAQ:VRTX) completed its approximately $10 billion equity-value acquisition of Crinetics Pharmaceuticals on September 1, 2026.
Tue, 01 Sep 2026 15:07:07 +0000
- Vertex Pharmaceuticals Up 15% in a Month: How to Play the Stock
Vertex's stock is up 15% in a month as strong CF sales, rising non-CF drug revenues and renal pipeline progress boost its growth story.
Wed, 26 Aug 2026 13:33:00 +0000
- Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead
Don't bet against Vertex Pharmaceuticals in cystic fibrosis.
Thu, 20 Aug 2026 19:50:00 +0000